New Target for Brain Injury Repair Identified: dBcAMP Delivers Neuroprotection and Cognitive Improvement

A recent animal study published in Frontiers in Behavioral Neuroscience found that dibutyryl cyclic adenosine monophosphate (dBcAMP), a cell-permeable cAMP analog, protects damaged hippocampal neurons, boosts neurogenesis, and restores memory function, offering a candidate molecule for novel drugs against cognitive and brain injuries.

In this research, a kainic acid-induced excitotoxic hippocampal injury mouse model was established. Injured mice received intraperitoneal injections of dBcAMP at 50 mg/kg daily for one week. Morris water maze and passive avoidance tests revealed no significant differences in learning capacity across all groups. However, injured mice without treatment suffered severe memory loss, while dBcAMP-treated mice exhibited remarkable memory recovery, with far longer target quadrant residence time and dark compartment entry latency.

Tissue staining verified that dBcAMP blocks neuronal death in the CA3 and dentate hilus regions of the hippocampus and sharply raises the count of DCX-labeled newborn neurons. Mechanistically, it activates the cAMP pathway, upregulates BDNF, enhances astrocytic glutamate transport, relieves excitotoxicity, and accelerates the proliferation and differentiation of neural progenitor cells.

Current clinical therapies lack drugs that simultaneously protect neurons and repair cognition. As a small molecule with high cell permeability, dBcAMP is easy to administer and promising for central nervous system drug development. Industry insiders note it holds unique potential for traumatic brain injury and epilepsy-induced cognitive impairment. Further formulation optimization and long-term safety evaluations are required to advance its clinical translation.

FOR DETAIL:  https://doi.org/10.3389/fnbeh.2020.00018

Article from: